2-(4-Methoxyphenyl)-6,7-dimethyl-4-oxochromene-8-carboxylic acid | 129696-95-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 2-(4-Methoxyphenyl)-6,7-dimethyl-4-oxochromene-8-carboxylic acid
• CAS: 129696-95-3
• 化学式: C₁₉H₁₆O₅
• 分子量: 324.333
• InChiKey: GMXSJYMZSFKIPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-Methoxyphenyl)-6,7-dimethyl-4-oxochromene-8-carboxylic acid 在 氢碘酸 、 溶剂黄146 作用下， 反应 24.0h， 以59%的产率得到6,7-dimethyl-2-(4'-hydroxyphenyl)-4-oxo-4H-1-benzopyran-8-carboxylic acid
  参考文献：
  名称：

  Synthesis of flavone-8-carboxylic acid analogues as potential antitumor agents

  摘要：

  Furan o-aminonitriles may be utilized as precursors in the synthesis of flavone-8-carboxylic acids. Some results from in vivo evaluation against P388 leukemia, colon carcinoma 38, and B16 melanoma models suggest that selected examples of the acids are potentially as effective as the antitumor compound, flavone acetic acid. The flavone-8-carboxylic acids did not exhibit significant activity against an in vitro HIV screen or an in vitro antitumor screen consisting of a cell panel of 60 lines.

  DOI：

  10.1016/0223-5234(93)90127-z
• 作为产物：
  描述：

  3-cyano-4,5-dimethyl-2-hydroxyacetophenone 在 吡啶 、 氢氧化钾 、 磷酸 、 硫酸 、 sodium acetate 、 三乙胺 、 尿素 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 溶剂黄146 为溶剂， 反应 11.5h， 生成 2-(4-Methoxyphenyl)-6,7-dimethyl-4-oxochromene-8-carboxylic acid
  参考文献：
  名称：

  Cutler, Stephen J.; El-Kabbani, Fiesal M.; Keane, Charlene, Heterocycles, 1990, vol. 31, # 4, p. 651 - 661

  摘要：

  DOI：

文献信息

• Cell death triggered by synthetic flavonoids in human leukemia cells is amplified by the inhibition of extracellular signal-regulated kinase signaling
  作者：Sara Rubio、Francisco León、José Quintana、Stephen Cutler、Francisco Estévez

  DOI：10.1016/j.ejmech.2012.07.028

  日期：2012.9

  A new class of methyl esters of flavonoids, with different substituents on the B ring were synthesized and evaluated for their antiproliferative activity against the human leukemia cell line HL-60. The presence of either a methyl group (1f) or a chlorine atom (1o) at position 2' of the B ring played an important role in affecting antiproliferative activity. The cytotoxic effects of these compounds were accompanied by the concentration- and time-dependent appearance of DNA- and nuclear-fragmentation, increase in the percentage of sub-G(1) cells, and processing of multiple caspases and poly(ADP-ribose)polymerase cleavage. Pretreatment of cells with the specific mitogen-activated extracellular kinases (MEK) 1/2 inhibitor PD98059, together with if and 1o, resulted in an important enhancement of cell death, which might have clinical implications for the use of both compounds in combination with MEK 1/2 inhibitors as potential therapeutic agents. (C) 2012 Elsevier Masson SAS. All rights reserved.
• CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET
  申请人：Centre National de la Recherche Scientifique

  公开号：EP3436601A1

  公开（公告）日：2019-02-06
• [EN] CYTIDINE DEAMINASE EXPRESSION LEVEL IN CANCER AS A NEW THERAPEUTIC TARGET<br/>[FR] NIVEAU D'EXPRESSION DE LA CYTIDINE DÉSAMINASE DANS UN CANCER EN TANT QUE NOUVELLE CIBLE THÉRAPEUTIQUE
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2017167989A1

  公开（公告）日：2017-10-05

  The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.